FDA Approves New Migraine Medication

The U.S. Food and Drug Administration (FDA) recently approved the first oral calcitonin gene-related peptide (CGRP) receptor antagonist specifically designed for migraine prevention. The drug atogepant (Qulipta) was approved to prevent episodic migraine in adults. Similar drugs, in monoclonal antibody form, are injected, but atogepant is an oral medication taken once daily. The FDA’s decision was supported, in large part, by a study that found people who regularly experience migraines had, on average, three to four fewer migraine days per month after taking the medication for 12 weeks. Possible side effects include constipation, nausea, and fatigue. The medication, however, is generally well tolerated. If you experience migraines, talk with your doctor about atogepant and other lifestyle changes you can make to prevent or at least reduce the frequency and severity of migraine headaches in your life. 

The post FDA Approves New Migraine Medication appeared first on University Health News.

Read Original Article: FDA Approves New Migraine Medication »